Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus THEOBID JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus THEOBID JR.
DILOR-400 vs THEOBID JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Inhibits phosphodiesterase, increasing intracellular cAMP; causes bronchodilation, central nervous system stimulation, and positive inotropic/chronotropic effects.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
300 mg orally every 12 hours, extended-release tablet. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
3-8 hours in adults; prolonged in neonates, cirrhosis, heart failure (up to 30 hours). Tobacco smoking induces clearance (half-life 4-5 hours).
Renal (70% unchanged), hepatic metabolism (30%)
Hepatic metabolism (90%), renal excretion of unchanged drug (10%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator